Standard BioTools Inc. (NASDAQ:LAB) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 188.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,445,083 shares of the company's stock after acquiring an additional 1,597,728 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.66% of Standard BioTools worth $4,719,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in LAB. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Standard BioTools by 20.2% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 10,642,271 shares of the company's stock valued at $18,837,000 after purchasing an additional 1,788,780 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Standard BioTools by 1,019.8% during the second quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company's stock valued at $1,736,000 after acquiring an additional 893,383 shares in the last quarter. Royce & Associates LP increased its position in shares of Standard BioTools by 102.0% during the third quarter. Royce & Associates LP now owns 614,552 shares of the company's stock worth $1,186,000 after acquiring an additional 310,321 shares during the last quarter. Rhumbline Advisers increased its position in shares of Standard BioTools by 3,691.1% during the second quarter. Rhumbline Advisers now owns 407,467 shares of the company's stock worth $721,000 after acquiring an additional 396,719 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its stake in shares of Standard BioTools by 130.1% in the second quarter. Squarepoint Ops LLC now owns 305,516 shares of the company's stock worth $541,000 after acquiring an additional 172,738 shares in the last quarter. Hedge funds and other institutional investors own 53.74% of the company's stock.

Standard BioTools Price Performance

LAB traded down $0.01 during trading on Friday, hitting $1.91. The company had a trading volume of 1,368,306 shares, compared to its average volume of 2,403,563. Standard BioTools Inc. has a 1-year low of $1.21 and a 1-year high of $3.04. The company has a market cap of $711.01 million, a PE ratio of -2.69 and a beta of 1.61. The business has a 50-day moving average of $1.85 and a 200-day moving average of $1.95.

Analysts Set New Price Targets

Separately, TD Cowen lowered their price objective on Standard BioTools from $2.75 to $2.50 and set a "buy" rating for the company in a research note on Thursday, October 31st.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.